MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc.

Core Viewpoint - Marinus Pharmaceuticals, Inc. is facing a securities class action lawsuit due to alleged failures in disclosing risks related to its clinical trials, leading to significant stock price declines [2][6][7]. Group 1: Legal Action - A securities class action lawsuit has been filed against Marinus Pharmaceuticals for alleged violations of the Securities Exchange Act of 1934, covering the period from March 17, 2021, to May 7, 2024 [6]. - The lawsuit claims that Marinus failed to disclose the risk of not meeting early-stopping criteria in the RAISE trial, which could impact the RAISE II trial [2][6]. Group 2: Stock Performance - Following the announcement of cost-cutting measures and the failure of the RAISE trial to meet early stopping criteria, Marinus' stock price fell over 82%, closing at $1.30 per share on April 15, 2024 [3][13]. - On May 8, 2024, the stock price dropped nearly 9%, closing at $1.43 per share [3]. Group 3: Company Actions - Marinus announced several cost-cutting measures, including halting clinical trial enrollment in the RAISE and RAISE II trials, deferring manufacturing investments, and reducing its workforce by approximately 20% [7]. - The company aims to increase operational efficiency through additional cost reductions across R&D and general and administrative functions [7][10].